Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 4 Next >
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces ADS Ratio Change
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Granted Key NASH Patent in Israel
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.